IOVA vs ISRG
Iovance Biotherapeutics, Inc. vs Intuitive Surgical — AI-powered side-by-side comparison
IOVA
Iovance Biotherapeutics, Inc.
65
Buy
VS
ISRG
Intuitive Surgical
60
Buy
| Metric | IOVA | ISRG |
|---|
| AI Score |
65
|
60
|
| Price |
$8.45
|
$371.73
|
| P/E Ratio |
-11.51×
|
42.21×
|
| ROE |
-56.0%
|
16.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
116.3%
|
66.7%
|
| Debt / Equity |
0.06×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
67.0
|
40.0
|
| Beta |
0.701
|
1.46
|
| Expected Upside |
—
|
+18.5%
|
AI Committee View
Current Innellis committee reasoning for IOVA versus ISRG.
IOVA leads by 5 points.
IOVA scores 65/100 (Buy) versus ISRG at 60/100 (Buy).
IOVA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- Weekly RSI at 79 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 97.8% signals elevated volatility — Risk
ISRG Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 17.8% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 45.2 is expensive by classic value standards — Value
- Price-to-book of 11.3x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical